BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lei J, Zhong J, Luo Y, Yan L, Zhu J, Wang W, Li B, Wen T, Yang J; Liver Surgery Group. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget 2017;8:91328-42. [PMID: 29207647 DOI: 10.18632/oncotarget.20511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Sangiovanni A, Colombo M. Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it? Hepatobiliary Surg Nutr 2018;7:202-5. [PMID: 30046574 DOI: 10.21037/hbsn.2018.03.12] [Reference Citation Analysis]
2 Ogawa K, Kaido T, Okajima H, Fujimoto Y, Yoshizawa A, Yagi S, Hori T, Iida T, Takada Y, Uemoto S. Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2019;26:73-81. [PMID: 30561147 DOI: 10.1002/jhbp.602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
3 Dinorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Annals of Surgery 2020;271:616-24. [DOI: 10.1097/sla.0000000000003253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
4 Huang H, Chen T, Zhou Y, Geng L, Shen T, Zhou L, Zheng S. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci 2018;15:1648-57. [PMID: 30588188 DOI: 10.7150/ijms.28289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Bartnik K, Hołówko W, Rowiński O. Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. Life (Basel) 2021;11:1062. [PMID: 34685433 DOI: 10.3390/life11101062] [Reference Citation Analysis]
6 Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn HM, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146:1819-27. [PMID: 32356179 DOI: 10.1007/s00432-020-03215-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lee SY, Ou HY, Yu CY, Huang TL, Tsang LL, Cheng YF. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter? Diagn Interv Radiol 2020;26:230-5. [PMID: 32352922 DOI: 10.5152/dir.2019.19261] [Cited by in F6Publishing: 1] [Reference Citation Analysis]